ExpertsFMNovo Nordisk (Ozempic)
Acquired · January 22, 2024
5 Selected Lessons:
framework · 2 heuristic · 1 case · 1 priority · 1
Long-term focus and narrow concentration as the core explanatory variable for Novo Nordisk's success
Source
When this applies
when identifying the single most important causal factor behind a company's multi-decade compounding success
The takeaway
Long-term focus on a single large/compounding market, protected from short-term pressure, is a necessary (though not sufficient — luck and correct execution are still required) condition for the kind of compounding that produces category-defining breakthroughs.
Why it works
Staying concentrated in one disease area for a century, protected by a governance structure insulated from short-term shareholder pressure, allowed accumulated domain expertise (molecule engineering, delivery mechanisms, half-life extension techniques) to compound across decades, directly enabling the semaglutide breakthrough.
One level up
Durable compounding advantage comes from sustained focus over decades rather than diversification or opportunistic pivoting, but focus alone does not guarantee the breakthrough — it must be paired with being in a big enough market and a bit of luck.
Where it stops holding
This stops working when the chosen market never becomes large (as insulin wasn't for the first 60 years), or when the company lacks the governance protection to stay focused through periods of doubt — hence why 'not every focused company becomes a Novo.'
Detail
hierarchy:
- 1. Decades-long focus on one disease area, enabling compounding domain expertise
- 2. Governance insulated from short-term pressure (foundation control, no stock options for execs)
- 3. Being in a market that eventually becomes enormous (type 2 diabetes/obesity explosion)
- 4. Some amount of luck in timing and scientific discovery
rationale: I'm tempted to say from this whole episode that the moral of the story here is focus and long-term focus, but I feel like we need to uncover this industry more and hear from folks in it. If that were always true, why are there not more novos out there?
In their words
The key point is long-term focus. And if you can do that, as we've shown time and time again on this show, you can create something great. If you do that, it's not like you will create something great. You still got to get lucky and also be doing the right things in the right areas.
Seven Powers applied to pharma: cornered resource + scale economies dominate
Source
Acquired — Novo Nordisk (Ozempic) (January 22, 2024) · at 2:42:06 ▸ · at 2:45:24 ▸ · at 2:48:40 ▸ · at 2:50:52 ▸
When this applies
when assessing which structural power(s) let any company sustain above-market returns versus competitors
The takeaway
In regulated, patent-driven, capital-intensive industries, durable competitive advantage usually stacks from a small number of powers (cornered resource, scale economies, switching costs) rather than network effects or counter-positioning, which rarely apply to incumbents.
Why it works
Patents create a temporary N-of-one monopoly (cornered resource); the enormous capital requirements of R&D, production, and go-to-market create scale economies that smaller entrants can't match; switching costs lock in patients once a drug works for them.
One level up
Apply a structured power framework to identify which 1-2 powers actually drive an industry's economics, rather than assuming all forms of moat apply equally everywhere.
Where it stops holding
This stops working when patents expire without a next-generation product in the pipeline, or when biosimilars/generics erode the cornered resource (as happened to insulin).
Detail
procedure:
- Identify where patents create monopoly molecules (cornered resource).
- Identify where R&D/production/go-to-market capital intensity excludes smaller players (scale economies).
- Identify where patient habit/response locks in usage (switching costs).
- Check for brand power specifically if the drug becomes a cultural buzzword.
- Dismiss counter-positioning and network economies as generally absent for incumbents in mature regulated industries.
benchmarks: {"drug approval cost":"$2.3 billion average","patent life":"semaglutide patent until 2032"}
rationale: Novo's profits evaporate within ~2 years of patent expiry historically (pre-biologics era), showing how central cornered resource power is to pharma economics.
In their words
So the first thing I want to say is we are in the pharma industry. And so the one that has a blinking red light around it is cornered resource.
Mapping a fragmented multi-party value chain before judging pricing
Source
Acquired — Novo Nordisk (Ozempic) (January 22, 2024) · at 1:17:26 ▸ · at 1:19:46 ▸ · at 1:23:11 ▸ · at 1:25:53 ▸
When this applies
when a transaction has many intermediaries and the nominal 'price' is disconnected from the actual value exchanged
The takeaway
Before analyzing or criticizing pricing in a market, map every intermediary in the chain and identify where rebates/markups are negotiated and who actually captures them — the sticker price is rarely informative in isolation.
Why it works
Each intermediary (distributor, pharmacy, PBM, insurer, employer) inserts a negotiated rebate/markup layer that obscures true price signals, so the 'sticker price' becomes largely fictional (e.g., 75% of insulin's sticker price is rebated away) and demand signals from the end customer never clearly reach the manufacturer.
One level up
In markets with many layered intermediaries, assume the posted price is a negotiating fiction, not a market-clearing price, and seek the actual net transaction data instead.
Where it stops holding
This stops working when a market has few or no intermediaries and list prices directly reflect what customers pay.
Detail
procedure:
- Identify the manufacturer, distributor/wholesaler, pharmacy, PBM, insurer, and employer in the chain.
- Determine which parties negotiate rebates (PBM negotiates with manufacturer) versus straightforward markups (distributor, pharmacy).
- Recognize PBM consolidation (3 PBMs control ~80% of the US market, covering 266 million Americans) gives them gatekeeper power over which drugs reach patients.
- Treat the sticker/list price as largely symbolic once large rebates are netted out.
benchmarks: {"rebate share":"Eli Lilly states rebates account for 75% of insulin's sticker price","PBM concentration":"3 PBMs cover ~80% of the US market"}
rationale: You can see how demand signals from patient and actual sort of clearing prices of a patient and what they're willing to pay for a drug, all that signal just gets lost in all of this middleman mania.
In their words
Eli Lilly has publicly claimed that the cost of these discounts and rebates accounted for 75% of the sticker price of insulin.
Counter-positioning via price and format upstart
Source
Acquired — Novo Nordisk (Ozempic) (January 22, 2024) · at 42:52 ▸ · at 2:50:52 ▸
When this applies
when a challenger lacks the credibility/branding of an incumbent and must win through a structurally different product or pricing approach the incumbent can't easily copy
The takeaway
If you can't out-credential an incumbent, out-engineer them on a dimension (cost structure, format, convenience) that undermines their positioning rather than imitating their playbook.
Why it works
A new entrant with engineering/operational strengths (rather than scientific prestige) can win by reformulating the product (e.g., liquid vs. tablet) to be both better and structurally cheaper, which the incumbent is reluctant to match due to reputational or capability constraints.
One level up
Startups counter-position; incumbents rarely counter-position back, because doing so would cannibalize their existing credibility or revenue.
Where it stops holding
This stops working when the incumbent's credibility advantage doesn't matter to customers, or when the format change doesn't deliver a genuine efficiency/cost benefit.
Detail
rule: Launch a structurally different, cheaper, more convenient product when you can't win on credentials.
threshold: Novo sold liquid insulin at half the price of Nordisk's tablets because the new production process was dramatically more efficient.
rationale: Ivory-tower incumbents often can't credibly chase a counter-positioned low-cost/high-convenience competitor without undermining their own premium positioning.
In their words
So, Novo, scrappy, upstart, counter positioned, and competition drives innovation. So they create better product.
Lata Biera Knudsen's persistence against an internal kill-ultimatum
Source
Acquired — Novo Nordisk (Ozempic) (January 22, 2024) · at 1:40:09 ▸ · at 1:43:24 ▸
When this applies
when an internal champion faces an organizational deadline/ultimatum to prove out a high-uncertainty bet or have it killed
The takeaway
A sufficiently motivated internal champion, given even a narrow survival window, can crack a problem the broader field has written off if the underlying mechanism is tractable with enough iteration.
Why it works
Continued iteration on a molecule's structure (adding a fatty acid to extend half-life) eventually solved a problem the rest of the field had abandoned as intractable, converting a 2.5-minute-half-life hormone into a viable drug candidate.
One level up
Breakthrough science often survives on an individual's refusal to quit exactly up to the point an organization is ready to abandon it.
Where it stops holding
This stops working when the underlying scientific/technical problem is genuinely intractable rather than merely unsolved, or when the organization doesn't give the champion even a narrow window to try.
Detail
situation: The academic/industry research community abandoned GLP-1 as a drug candidate because natural GLP-1 degrades in ~5 minutes; management gave Lata's team an ultimatum: find a viable candidate within a year or the program would be shut down.
decision: Lata kept tweaking the GLP-1 molecule, eventually grafting a fatty acid onto it to bind it to albumin and protect it from degradation.
outcome: Created liraglutide with a 13-hour half-life, satisfying the ultimatum and eventually leading (after a decade more of trials) to Victoza, then to semaglutide/Ozempic/Wegovy.
lesson: An internal champion's sustained technical iteration, even against a near-term kill deadline, can unlock an entire new drug category and company transformation.
In their words
So she keeps tweaking the GLP-1 molecule. And again, you can do this with recombinant DNA. You can tweak any molecule. So eventually, she develops a GLP-1 analog, analog being, you know, similar type molecule called Lyraglutide that includes a fatty acid grafted onto the molecule that helps prevent the body from breaking it down.